One of the major complications after allogeneic stem cell transplantation (SCT) in patients
with malignant disease is a high frequency of relapse. We have prospectively analyzed the …

Chimerism testing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in
patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) …

Recently, we have shown that patients with acute leukaemias and myelodysplastic
syndromes (MDS), who showed increasing mixed chimaerism (MC) upon serial PCR …

The role of chimerism analysis as a prognostic indicator of relapse after hematopoietic stem
cell transplantation (SCT) is controversial. We monitored chimerism status by short tandem …

Increasing mixed chimerism (MC) after allogeneic stem cell transplantation (SCT) has been
associated with a high risk of relapse in acute leukemia. We evaluated a new method for …

BACKGROUND AND OBJECTIVES: The role of hematopoietic chimerism after allogeneic
stem cell transplantation (SCT) for acute leukemia remains controversial. We studied the …

Abstract Analysis of donor chimerism is an important diagnostic tool to assess the risk of
relapse after allogeneic stem cell transplantation, especially in patients lacking a specific …

OBJECTIVE: Chimerism is well-established for surveillance of acute myeloid leukemia
(AML) patients after allogeneic hematopoietic stem cell transplantation (HSCT), but …

Relapse of the underlying malignant disease represents one of the major causes of
treatment failure in patients treated with stem cell transplantation, especially in patients with …

Recipient–donor chimerism is routinely analyzed after allogeneic hematopoietic stem cell
transplantation (HSCT) to monitor engraftment and graft rejection. For malignancies …